Environmentally adjusted lipidomic metabolic age score tested in four cohorts
Researchers built an environmentally adjusted metabolic age score from plasma lipid profiles and report it was more consistently linked to dementia, cardiovascular events and death than an unadjusted lipidomic age model. [1]
Automatic summary · not editorially reviewed
The key findings
EAmAge was derived in the AusDiab cohort (n = 10,339) after major environmental influences were statistically removed from plasma lipidomic profiles. [1]
EAmAge was validated in three independent cohorts (BHS, ADNI and ASPREE; total n = 9,835). [1]
Compared with an unadjusted lipidomic age model, EAmAge showed stronger and more consistent associations with incident Alzheimer's disease-related dementia, cardiovascular events and all-cause mortality. [1]
The source at a glance
- Study type / format
- Abstract of a cohort-based biomarker development and validation study
- Population / context
- Participants in the AusDiab, BHS, ADNI and ASPREE cohorts (total n = 20,174 across derivation and validation).
- Summary based on
- Study abstract
- Publication status
- Preprint · peer-review status not confirmed
- Original publication
- June 9, 2026
Adjusted lipidomic age score built in AusDiab
The authors describe biological age scores as capturing ageing differences beyond chronological age, but note these are often dominated by lifestyle and environmental exposures. To isolate what they call intrinsic ageing biology, they statistically removed major environmental influences from plasma lipidomic profiles and then built an age-prediction model using ridge regression. The resulting score, EAmAge, was derived in the AusDiab cohort with 10,339 participants.
Supporting source [1]
Validation in three cohorts and outcome links
EAmAge was validated in three independent cohorts, BHS, ADNI and ASPREE, with a total of 9,835 participants. Compared with an unadjusted lipidomic age model (mAge_orig), EAmAge showed stronger and more consistent associations with incident Alzheimer's disease-related dementia, cardiovascular events and all-cause mortality. It was also associated with Alzheimer's disease-related biomarkers, including amyloid burden, reduced glucose metabolism and hippocampal atrophy. These are associations, not evidence that the score causes these outcomes.
Supporting source [1]
Abstract-only scope and biomarker framing
The authors describe EAmAge as a robust and partially modifiable biomarker that may improve risk stratification by separating intrinsic metabolic ageing from environmental confounding. The available text is an abstract; the full text was not reviewed. Details such as follow-up length, how environmental factors were defined, and the exact outcome definitions are not reported here, so the strength and clinical usefulness of the score remain to be judged from the full study.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. Follow-up duration, definitions of environmental factors and outcome ascertainment are not reported in the supplied text. Reported links are associations, not causal effects.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Meikle P, Wang T, Beyene H, Yi C, Duong T, Mellett N, Meikle T, Wu J, Dakic A, Cinel M, Watts G, Hung J, Hui J, Beilby J, Blangero J, Salim A, Moses E, Arnold M, Kastenmüller G, Han X, Blach C, Yu C, McNeil J, Lacaze P, Nho K, Saykin A, Shaw J, Magliano D(, Kaddurah-Daouk R, Giles C, Huynh K. · europepmc.org · June 9, 2026